KriyaBio, a pharmaceutical company based in Geneva, Switzerland, offers drug delivery solutions that utilize their proprietary permeation enhancer KB01. By replacing the current method of intravitreal injections with eye drops, KriyaBio improves patient safety, compliance, and reduces healthcare costs. This breakthrough has significant implications for the treatment of age-related macular degeneration (AMD) and represents a game changer in the field. Founded in 2020, KriyaBio aims to deliver medical drugs that enhance patient safety and compliance while reducing healthcare burdens.